Table 5.
Clinical outcomes of response to therapy evaluation guided RAT.
| Study | Study design | Number | Follow-up period | Tg cut-off (ng/ml) | Endpoint | Prognosis improvedyes/no | Dosage | Benefited subgroups | |
|---|---|---|---|---|---|---|---|---|---|
| Pacini F et al. (2001) (41) | Retrospective | 70 | 6.7 ± 3.8 y | 7-207 | Tg levels | Yes | 90-150mCi | Lung metastases on RxWBS, (may in those with lymph node metastases on RxWBS) | |
| Tramontin MY et al. (2021) (42) |
Retrospective | 120 | 15.5 y | 10 | Tg levels, ATA response to therapy status and OS | No | 100-600mCi | Na | |
| Van Tol KM et al. (2003) (38) |
Retrospective | 56 | Median 4.2 y (0.5-13.5 y) | (Stimulated) 1.7-10700 | Suppressed Tg levels and 5-year survival | Yes | 150mCi | RxWBS+ group (more additional 131I treatment) | |
| Klain M et al. (2019) (43) |
Retrospective | 100 | 96 ± 75 m | 5 | PFS and OS | Yes | 165 ± 46 mCi | CR or PR | |
| Kim WG et al. (2010) (44) |
Prospective | 39 | Median 4.2 m (3-104 m) | 10 | Recurrence and stimulated Tg levels | No | 150mCi | Na | |
Here, only studies with long-term follow-up or large sample sizes are listed.
CR, complete remission; PR, partial remission; SD, stable disease, PD, progressive disease; PFS, progression-free survival; OS, overall survival; RxWBS, post therapy whole-body scan.